Transcribe your podcast
[00:00:00]

Everyone, Dr. David Hill here with my good friend, Dr. Russell Laska Thorpe. Russell, welcome. Thank you. Nice to have you here. I'd like to take a moment just to introduce herself. Sure you are. My name is Dr. Oz Thorpe. You can call me Dr.. I'm a pediatric infectious disease doctor, and I'm really glad to be at Doctora.

[00:00:17]

Well, we're happy to have you here. And today we're going to talk a little bit about Capalaba and CBD. I would like to put it into a context of four very specific things. And this is going to surprise you.

[00:00:28]

But price purity. Yeah, potency. And then I'd also like to talk about some new discovery we're making for pathway. Yeah. And I want to relate those all to CBD and this comparison to fiber. And one of the things that we know about CBD is that everybody has had seemingly great experience. We know that there's a good amount of information that's available and we don't want to be discounting of any of that. So let's just talk some very specific things.

[00:00:56]

When you think of those first three things, price, potency and purity, what comes to mind to you in the marketplace today?

[00:01:04]

CBD is flooded all over the place. It's in every product imaginable, from mascara to doggie treats and everything in between. The trouble is that when people are taking it to help them with problems that they have with their health, the doses that are required are so high that the price point is really painful.

[00:01:23]

Well, it becomes painful and becomes unobtainable for most people. And purity is a different animal for me. I'm going to drill them on this just a little bit.

[00:01:31]

It's still Tear's calling it. It's it's what we do. It's what we know.

[00:01:35]

And I know the intensity that goes with that.

[00:01:36]

And in an industry that, as you indicated, has this plethora of products, we see a lot of inconsistencies in terms of the amount that's available of the CBD, where some of the difference that you see that.

[00:01:48]

Well, the trouble with CBD is that the hemp industry where CBD comes from is not very regulated and the products that are made are not checked for purity. And the amount of CBD within those products can be highly variable because of the dissonance that exists between the federal and state statutes around CBD. Right. It's not a good time for us as a company to enter that arena. Let's look at the Indo cannabinoid system CB1 CB2 receptors.

[00:02:23]

Join me to explain it really quickly. A very quick for everybody to understand so that the endocannabinoid system in our body controls a whole host of things.

[00:02:30]

Eat, sleep, forget, relax, and the receptor tone matters and you change that receptor tone by these chemicals that our body makes for ourselves. We call them endocannabinoids. In the plant world. There are lots of chemicals that plants make that interact with our own body's receptors. They call they're called phyto cannabinoids. And CBD is one of those beta carotene as another. Right. And that potency issue, how much power you get to that system, either up regulating or down regulating that system depends on how you bind to those receptors.

[00:03:04]

And beta karrar offline is a direct binder to the system. Correct. And CBD is an indirect binder.

[00:03:10]

So this offers some explanation why we're not saying that CBD has no value. It's just a different circumstance. Correct, in the amount that we have present within those two products. By comparison, when we look at Captivities Santoya, when we look at CBD, they're very different, they're very different, and we really don't compare them. And this is one of the things that I've become most excited about with Kaposvar is that the beta carotene, this phyto cannabinoid that you talked about, that in and of itself resides in substantial amounts.

[00:03:42]

There's really little question about are we getting some efficacious dosages associated with that? The potency that you can obtain by getting a purified product from Capalaba with better care of is quite high.

[00:03:54]

I really get excited about what we're currently discovering with Path Pathway. And so let's talk about that, because you've already indicated that one of the differences that we see as we activate this system and we're talking about CB2 receptors, we have indirect consequence and direct consequence in the downstream effect that both of those create that we're after. So binding at the receptor level is really important. But what matters in the cell is how you get to your end result, which is changing DNA, proteins, enzymes, the cellular functions and direct binding at these receptors has effects that will drive cellular mechanisms to change certain outcomes within the body.

[00:04:42]

One of the other things that I have liked about Capalaba as an essential oil product is the diversity that we see. It's not just Feydeau cannabinoid that's there. It's not just the Medicare Offaly. We have lots of other chemistry and that provides some diversity for us. And so unlike. The CBD, when we look at Capalaba as an essential oil, we have potential for other benefits that really can even reside outside of the endocannabinoids.

[00:05:09]

When we when we talk about Capalaba, we're not just talking about Baedeker offline. I agree. There are many molecules within the essential oil, many of which have plant chemistry behind them, where we know that there are going to be other effects than just simply the endocannabinoid system, Baedeker offline. However, being a major component, and that's one of the things that we love about it, is that we're confident we have potency. We know that we have purity and we know that it's directed to the cannabinoid system.

[00:05:40]

I've seen a bottle of CBD sometimes sell for hundreds of dollars. Sure. And the amount that I would have to consume based on the discussion that we've had is exponentially higher than what we would see with something like Capalaba that has higher chemistry, certainly not hundreds of dollars a bottle. And we've also know and have looked at the research and know that by comparison we can have very small dosage amounts and still create the benefit in the effect that we're looking for.

[00:06:09]

That, to me, is one of the critical things. I get greater benefit from the co-payment and higher value. I get greater efficacy and I have much higher value.

[00:06:17]

I come back to as well those four P's. I think it's the foundation of what DR does. Purity and price are extremely important when you're talking about a product like this. And I think that Capalaba will define itself in the marketplace quite nicely over time.